Ranbaxy’s $500 Million Settlement Includes Criminal Penalties
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic drug maker’s Ranbaxy USA Inc. subsidiary pleads guilty to seven felony counts brought in connection with a longstanding government investigation into data integrity issues and manufacturing violations at two Indian sites, but while the settlement eliminates some worries for the firm, operations still face the weight of a FDA consent decree.